Evidence mapPaperPMID 34084153Full record

Trial reportFrontiers in endocrinology2021

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass.

Isabella Jonsson, Kirstine N Bojsen-Møller, Viggo B Kristiansen, Simon Veedfald, Nicolai J Wewer Albrechtsen, Trine R Clausen, Rune E Kuhre, Jens F Rehfeld, Jens J Holst, Sten Madsbad and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06132477 (Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06132477 phase4recruitingstarted 2024, after this paper: background citation

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Ran2024Enrolled150Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Hypertension, Metabolic Syndrome, Morbid ObesityArmsGLP-1 receptor agonist
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Isabella JonssonDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
Kirstine N Bojsen-MøllerDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
Viggo B KristiansenDepartment of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.
Simon VeedfaldNovo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Nicolai J Wewer AlbrechtsenNovo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Trine R ClausenResearch and Development, Novo Nordisk A/S, Måløv, Denmark.
Rune E KuhreNovo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jens F RehfeldDepartment of Clinical Biochemistry Rigshospitalet, Copenhagen, Denmark.
Jens J HolstNovo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Sten MadsbadDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
Maria S SvaneDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
Hvidovre Hospital · DKNovo Nordisk (Denmark) · DKUniversity of Copenhagen · DKNovo Nordisk Foundation · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Altered bile acid (BA) turnover has been suggested to be involved in the improved glucose regulation after Roux-en-Y gastric bypass (RYGB), possibly Methods: Two single-blinded randomized cross-over studies were performed. In study 1, eight RYGB operated participants ingested 200 ml water with 1) CDCA 1.25 g or 2) CDCA 1.25 g + colesevelam 3.75 g on separate days. In study 2, twelve RYGB participants ingested on separate days a mixed meal with addition of 1) CDCA 1.25 g, 2) COL 3.75 g or 3) COL 3.75 g × 2, or 4) no additions. Results: In study 1, oral intake of CDCA increased circulating BAs, GLP-1, C-peptide, glucagon, and neurotensin. Addition of colesevelam reduced all responses. In study 2, addition of CDCA enhanced meal-induced increases in plasma GLP-1, glucagon and FGF-19 and lowered plasma glucose and C-peptide concentrations, while adding colesevelam lowered circulating BAs but did not affect meal-induced changes in plasma glucose or measured gastrointestinal hormones. Conclusion: In RYGB-operated persons, exogenous CDCA enhanced meal-stimulated GLP-1 and glucagon secretion but not insulin secretion, while the BA sequestrant colesevelam decreased CDCA-stimulated GLP-1 secretion but did not affect meal-stimulated GLP-1, C-peptide or glucagon secretion, or glucose tolerance. These findings suggest a limited role for endogenous bile acids in the acute regulation of postprandial gut hormone secretion or glucose metabolism after RYGB.

Indexed as

Gastric BypassAdultBile Acids and SaltsBlood GlucoseColesevelam HydrochlorideC-PeptideFemaleGlucagonGlucagon-Like Peptide 1GlucoseHumansMaleMiddle AgedNeurotensinObesity, MorbidPostprandial PeriodBile Acids and SaltsBlood GlucoseColesevelam HydrochlorideC-PeptideGlucagonGlucagon-Like Peptide 1GlucoseNeurotensinbile acidscolesevelamglucagon-like peptide 1Roux-en-Y gastric bypassRYGB

Identifiers

PMID34084153
PMCPMC8166580
OpenAlexW3160889129

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.